Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.
Testicular, Penile, and Rare Malignancies
Advertisement
Latest News
Guidance addresses prepubic fat coverage and dose fractionation for both neoadjuvant and adjuvant settings.
The EPIC-A trial has demonstrated the efficacy and safety of cemiplimab combined with platinum-based chemotherapy for la/mPC.
Specificity findings varied, but some studies suggested similar or slightly higher rates in favor of MRI.
There is a lack of data on 1L regimens for distant metastatic PSCC, with a 2-year OS rate of just 21%.
Drs. Necchi and Tawagi highlight some the challenges in penile cancer, including "suboptimal" neoadjuvant, adjuvant options.
Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Advertisement
Advertisement
Trending
Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.
Almost 30% of patients will experience recurrence while undergoing EBRT that will require ADT and salvage therapies.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.